Example searches

TENX Tenax Therapeutics, Inc.

All TENX filings Filing statistics SEC
Tenax Therapeutics, Inc. is a pharmaceutical company, which engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its product candidate includes Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

Company profile

Ticker
TENX
Exchange
NASDAQ
Website
www.tenaxthera.com
CEO
Anthony A. DiTonno
Employees
Incorporated in
Delaware
Location
North Carolina
Fiscal year end
Dec 31
Sector
Health Technology > Medical Specialties
Industry (SEC)
Services - Commercial Physical & Biological Research
PRA Health Sciences • Charles River Laboratories International • Syneos Health • Medpace • Incyte • Intrexon • Exelixis • ICON • EXACT Sciences • National Research ...
Former names
Oxygen Biotherapeutics, Inc., Synthetic Blood International Inc
SEC CIK
0000034956
Corporate docs
IRS number
262593535

TENX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

14 Nov 19
15 Dec 19
31 Dec 19

News

Company financial data Financial data

Chart TENX financial data
Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue
Net income 2.22M 1.76M 1.62M -18.74M
Diluted EPS -0.33 -0.28 -0.33 -5.86
Operating income 2.26M 1.82M 1.66M -11.56M
Net change in cash -1.76M -1.91M -2.05M 9.02M
Cash on hand 6.65M 8.41M 10.32M 12.37M
Cost of revenue
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 0
Net income -14.14M -8.84M -43.92M
Diluted EPS -9.04 -6.27 -31.24
Operating income -6.89M -9.21M -52.65M
Net change in cash 2.87M -12.4M -16.3M
Cash on hand 12.37M 9.5M 21.9M 38.2M
Cost of revenue 0

Financial data from company earnings reports

Financial report summary

?
Competition
Cytokinetics
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
From filing 10-Q 2019 Q3

Financial reports

View all
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
14 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19
10-K
2018 FY
Annual report
1 Apr 19
10-Q
2018 Q3
Quarterly report
14 Nov 18
10-Q
2018 Q2
Quarterly report
14 Aug 18
10-Q
2018 Q1
Quarterly report
15 May 18
10-K
2017 FY
Annual report
2 Apr 18
10-Q
2017 Q3
Quarterly report
9 Nov 17
10-Q
2017 Q2
Quarterly report
9 Aug 17

Current reports

View all
8-K/A
Submission of Matters to a Vote of Security Holders
8 Nov 19
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 19
8-K
Tenax Therapeutics Announces Closing of
11 Dec 18
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 18
8-K
Tenax Therapeutics Announces Appointment of
5 Jun 18
8-K
Other Events
14 Mar 18
8-K
Tenax Therapeutics Announces Reverse Stock Split
23 Feb 18
8-K
Submission of Matters to a Vote of Security Holders
15 Feb 18
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Sep 17
8-K
Tenax Therapeutics Provides Regulatory Update on Levosimendan
28 Jul 17

Registration and prospectus

View all
S-8
Registration of securities for employees
30 Aug 19
424B4
Prospectus supplement with pricing info
7 Dec 18
S-1/A
IPO registration (amended)
6 Dec 18
S-1/A
IPO registration (amended)
3 Dec 18
FWP
Free writing prospectus
20 Nov 18
S-1/A
IPO registration (amended)
20 Nov 18
S-1
IPO registration
6 Nov 18
S-3
Shelf registration
15 May 18
S-8
Registration of securities for employees
3 Apr 18
S-8
Registration of securities for employees
14 Mar 16

Proxies

View all
DEF 14A
Definitive proxy
19 Apr 19
DEF 14A
Definitive proxy
20 Apr 18
DEF 14A
Definitive proxy
16 Jan 18
PRE 14A
Preliminary proxy
29 Dec 17
DEF 14A
Definitive proxy
28 Apr 17
DEF 14A
Definitive proxy
26 Apr 16
DEF 14A
Definitive proxy
17 Aug 15
DEF 14A
Definitive proxy
12 Aug 14
PRE 14A
Preliminary proxy
31 Jul 14
DEF 14A
Definitive proxy
4 Feb 14

Other

View all
EFFECT
Notice of effectiveness
10 Dec 18
EFFECT
Notice of effectiveness
24 May 18
UPLOAD
Letter from SEC
22 May 18
CORRESP
Correspondence with SEC
21 May 18
CORRESP
Correspondence with SEC
6 Mar 15
EFFECT
Notice of effectiveness
6 Mar 15
CORRESP
Correspondence with SEC
3 Mar 15
UPLOAD
Letter from SEC
26 Feb 15
EFFECT
Notice of effectiveness
8 Sep 14
EFFECT
Notice of effectiveness
13 Jun 14

Ownership

View all
SC 13G/A
Tenax Therapeutics, Inc.
14 Feb 19
SC 13G
Tenax Therapeutics, Inc.
12 Feb 19
SC 13G
Tenax Therapeutics, Inc.
5 Feb 19
SC 13G
Tenax Therapeutics, Inc.
14 Dec 18
SC 13G/A
Tenax Therapeutics, Inc.
14 Feb 18
SC 13G/A
Tenax Therapeutics, Inc.
13 Feb 18
SC 13G/A
Tenax Therapeutics, Inc.
4 Jan 18
SC 13G/A
Tenax Therapeutics, Inc.
14 Feb 17
SC 13G/A
Tenax Therapeutics, Inc.
14 Feb 17
SC 13G/A
Tenax Therapeutics, Inc.
6 Jan 17